Clinical Characteristics and Prognosis of B-cell Acute Lymphoblastic Leukemia Patients with IKZF1 Deletion.
10.19746/j.cnki.issn.1009-2137.2025.04.006
- Author:
Li-Hua WANG
1
;
Yan GUO
1
;
Yuan ZHANG
1
;
Xiu-Feng WANG
1
;
Xian-Kai LIU
1
;
Yan HUANG
1
Author Information
1. Department of Hematology, The First Affiliated Hospital of Xinxiang Medical University, Xinxiang Key Laboratory of Molecular Diagnosis and Treatment of Lymphoma, Xinxiang 453100, Henan Province, China.
- Publication Type:Journal Article
- Keywords:
B-cell acute lymphoblastic leukemia
- MeSH:
Humans;
Ikaros Transcription Factor/genetics*;
Prognosis;
Gene Deletion;
Female;
Male;
Precursor Cell Lymphoblastic Leukemia-Lymphoma/genetics*;
Adult;
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma/genetics*;
Adolescent;
Young Adult;
Middle Aged
- From:
Journal of Experimental Hematology
2025;33(4):966-971
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To analyze clinical characteristics and prognosis of B-cell acute lymphoblastic leukemia (B-ALL) patients with IKZF1 deletion.
METHODS:72 patients with B-ALL admitted to our hospital from April 2020 to January 2023 were selected, IKZF1 deletion were detected, and clinical characteristics and prognosis were analyzed.
RESULTS:Among the 72 patients, a total of 32 patients (44.4%) were identified with IKZF1 deletions (IKZF1 + ). There was no statistically significant difference in basic clinical data between patients with normal IKZF1 (IKZF1 -) and those with IKZF1 + (P >0.05). The proportion of patients with IKZF1 + in Ph+ group was significantly higher than that in Ph- group (P < 0.05). The main types of IKZF1 + were exon 1-8 deletion (34.4%) and exon 4-7 deletion (31.2%). The median OS and PFS of IKZF1 - patients were significantly longer than those of IKZF1 + patients (OS: 26.0 months vs 16.0 months, χ 2=23.094, P < 0.05; PFS: 26.0 months vs 16.0 months, χ 2=11.150, P < 0.05). Among IKZF1 + patients, the median OS of patients who received allogeneic hematopoietic stem cell transplantation (allo-HSCT) was significantly longer than that of patients who did not receive allo-HSCT (no reached vs 15.0 months, χ 2=5.685, P < 0.05).
CONCLUSION:IKZF1 deletion is a risk factor affecting the prognosis of B-ALL patients.
